Physician profile
Darren Casey
NPI 1679531677
$7,900.49
in general payments reported to CMS, 2019-2025
30 companies · $605 in 2025
The $605 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $670 · 2020: $729 · 2021: $3,149 · 2022: $792 · 2023: $447 · 2024: $1,509 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,561.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,456.80 | 2021-2025 | |
| Abbvie INC. | $745.97 | 2019-2025 | Rinvoq |
| Genzyme Corporation | $602.16 | 2019-2025 | |
| Leo Pharma INC. | $581.55 | 2019-2023 | Adbry |
| Incyte Corporation | $565.79 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $401.24 | 2019-2024 | Aklief |
| Regeneron Healthcare Solutions, INC. | $369.46 | 2020-2025 | Dupixent |
| Allergan, INC. | $365.80 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $235.16 | 2019-2025 | |
| Janssen Biotech, INC. | $199.55 | 2019-2025 | Remicade, Stelara, Simponi |
| Almirall LLC | $186.72 | 2019-2024 | Seysara |
| Ucb, INC. | $161.75 | 2021-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $127.70 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $121.46 | 2022-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $119.15 | 2023-2025 | Zoryve |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $104.43 | 2020-2023 | |
| Lilly USA, LLC | $102.17 | 2019-2025 | Taltz, Ebglyss |
| Amgen INC. | $99.71 | 2021-2025 | Otezla |
| Pfizer INC. | $72.99 | 2019-2024 | |
| Botanix Sb INC | $72.35 | 2025 | Sofdra |
| Revance Therapeutics, INC. | $36.49 | 2024 | Daxxify |
| Nabriva Therapeutics, Plc | $35.74 | 2020-2021 | |
| Sebela Pharmaceuticals INC. | $22.86 | 2019 | |
| Sandoz INC. | $21.41 | 2021 | |
| Lnhc, INC | $18.57 | 2025 | Zelsuvmi |
| Celgene Corporation | $15.95 | 2019 | |
| Merz North America, INC. | $15.75 | 2019 | |
| Fidia Pharma USA INC. | $15.71 | 2024 | Hyalgan, Triluron, Hymovis |
| Mylan Pharmaceuticals INC. | $14.77 | 2019 | |
| Merck Sharp & Dohme LLC | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darren Casey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.